百洋医药
(301015)
| 流通市值：138.01亿 | | | 总市值：138.03亿 |
| 流通股本：5.26亿 | | | 总股本：5.26亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,627,105,173.24 | 3,751,291,789.24 | 1,840,874,860.51 | 8,094,458,068.74 |
| 营业收入 | 5,627,105,173.24 | 3,751,291,789.24 | 1,840,874,860.51 | 8,094,458,068.74 |
| 二、营业总成本 | 4,964,392,143.68 | 3,428,066,346.85 | 1,635,496,471.03 | 7,169,337,235.28 |
| 营业成本 | 3,523,550,499.42 | 2,383,156,639.69 | 1,181,508,227.26 | 5,220,659,643.58 |
| 税金及附加 | 40,786,475.85 | 28,676,242.45 | 9,296,766.43 | 43,955,505.47 |
| 销售费用 | 1,076,439,712.09 | 807,361,915.86 | 351,371,788.98 | 1,516,920,293.54 |
| 管理费用 | 219,004,095.59 | 141,441,987.15 | 65,412,264.55 | 280,553,399.49 |
| 研发费用 | 26,236,370.95 | 17,916,778.63 | 5,426,988.5 | 36,139,782.22 |
| 财务费用 | 78,374,989.78 | 49,512,783.07 | 22,480,435.31 | 71,108,610.98 |
| 其中:利息费用 | 76,736,342.17 | 48,241,399.81 | 21,627,783.41 | 80,092,315.85 |
| 其中:利息收入 | 9,949,478.04 | 7,024,956.87 | 3,106,272.37 | 13,635,219.99 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 74,113,450.58 | -25,747,207.09 | -24,154,284.33 | 1,715,871.08 |
| 加:投资收益 | -6,155,038.67 | -15,444,667.73 | -8,918,355.5 | 59,209,403.06 |
| 资产处置收益 | 31,878.14 | 31,878.14 | 18,355.17 | 925,017.58 |
| 资产减值损失(新) | -41,009,726.66 | -35,593,152.11 | -34,185,911.73 | -16,023,077.4 |
| 信用减值损失(新) | -6,414,804.76 | -2,412,698.12 | -5,369,154.04 | -11,827,892.28 |
| 其他收益 | 23,193,745.47 | 21,639,778.93 | 12,442,301.19 | 18,617,808.51 |
| 四、营业利润 | 706,472,533.66 | 265,699,374.41 | 145,211,340.24 | 977,737,964.01 |
| 加:营业外收入 | 1,484,974.69 | 801,716.12 | 29,201.34 | 2,432,118.77 |
| 减:营业外支出 | 12,668,782.07 | 6,531,613.96 | 1,986,431.98 | 13,542,466 |
| 五、利润总额 | 695,288,726.28 | 259,969,476.57 | 143,254,109.6 | 966,627,616.78 |
| 减:所得税费用 | 134,674,939.54 | 48,563,366.61 | 33,591,209.61 | 199,596,972.39 |
| 六、净利润 | 560,613,786.74 | 211,406,109.96 | 109,662,899.99 | 767,030,644.39 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 560,613,786.74 | 211,406,109.96 | 109,662,899.99 | 767,030,644.39 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 476,428,959.39 | 163,135,677.61 | 85,012,813.37 | 691,593,321.92 |
| 少数股东损益 | 84,184,827.35 | 48,270,432.35 | 24,650,086.62 | 75,437,322.47 |
| 扣除非经常损益后的净利润 | 409,722,863.44 | 177,374,302.56 | 99,966,953.05 | 655,947,072.73 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.91 | 0.31 | 0.16 | 1.32 |
| (二)稀释每股收益 | 0.87 | 0.31 | 0.16 | 1.28 |
| 八、其他综合收益 | -1,351,003.28 | 1,354,600.8 | 628,024.82 | -104,993.07 |
| 归属于母公司股东的其他综合收益 | -955,954.59 | 1,127,600.38 | 570,184.82 | -178,040.99 |
| 九、综合收益总额 | 559,262,783.46 | 212,760,710.76 | 110,290,924.81 | 766,925,651.32 |
| 归属于母公司股东的综合收益总额 | 475,473,004.8 | 164,263,277.99 | 85,582,998.19 | 691,415,280.93 |
| 归属于少数股东的综合收益总额 | 83,789,778.66 | 48,497,432.77 | 24,707,926.62 | 75,510,370.39 |
| 公告日期 | 2025-10-30 | 2025-08-29 | 2025-04-24 | 2025-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |